AstraZeneca, Daiichi Sankyo withdraw EU application for lung cancer treatment
AstraZeneca and Daiichi Sankyo have withdrawn their marketing authorisation application in the European Union (EU) voluntarily, intended for datopotamab deruxtecan …
Post
-
-
NB-4746 by Nura Bio for Amyotrophic Lateral Sclerosis: Likelihood of Approval
NB-4746 is under clinical development by Nura Bio and currently in Phase I for Amyotrophic Lateral Sclerosis. According to GlobalData, …
-
ACTUS-101 by Asklepios BioPharmaceutical for Pompe Disease: Likelihood of Approval
ACTUS-101 is under clinical development by Asklepios BioPharmaceutical and currently in Phase II for Pompe Disease. According to GlobalData, Phase …
-
Gamma-PN by GPN Vaccines for Streptococcal Pneumonia: Likelihood of Approval
Gamma-PN is under clinical development by GPN Vaccines and currently in Phase II for Streptococcal Pneumonia. According to GlobalData, Phase …
-
Apraglutide by Ironwood Pharmaceuticals for Short Bowel Syndrome: Likelihood of Approval
Apraglutide is under clinical development by Ironwood Pharmaceuticals and currently in Phase III for Short Bowel Syndrome. According to GlobalData, …
-
AROC-3 by Arrowhead Pharmaceuticals for IgA Nephropathy (Berger’s Disease): Likelihood of Approval
AROC-3 is under clinical development by Arrowhead Pharmaceuticals and currently in Phase II for IgA Nephropathy (Berger's Disease). According to …
-
EXO-CD24 by Nano24med for Acute Respiratory Distress Syndrome: Likelihood of Approval
EXO-CD24 is under clinical development by Nano24med and currently in Phase II for Acute Respiratory Distress Syndrome. According to GlobalData, …
-
Fosravuconazole by Eisai for Tinea Pedis (Athlete Foot): Likelihood of Approval
Fosravuconazole is under clinical development by Eisai and currently in Phase II for Tinea Pedis (Athlete Foot). According to GlobalData, …
-
Dexamethasone sodium phosphate SR by Taiwan Liposome for Osteoarthritis Pain: Likelihood of Approval
Dexamethasone sodium phosphate SR is under clinical development by Taiwan Liposome and currently in Phase III for Osteoarthritis Pain. According …
-
Glufosfamide by Eleison Pharmaceuticals for Metastatic Adenocarcinoma of The Pancreas: Likelihood of Approval
Glufosfamide is under clinical development by Eleison Pharmaceuticals and currently in Phase III for Metastatic Adenocarcinoma of The Pancreas. According …
-
VMT-01 by Perspective Therapeutics for Metastatic Melanoma: Likelihood of Approval
VMT-01 is under clinical development by Perspective Therapeutics and currently in Phase II for Metastatic Melanoma. According to GlobalData, Phase …
-
Hydrocodone IR by Elysium Therapeutics for Opium (Opioid) Addiction: Likelihood of Approval
Hydrocodone IR is under clinical development by Elysium Therapeutics and currently in Phase I for Opium (Opioid) Addiction. According to …
-
SNK-396 by Synerk for Lipid Disorders: Likelihood of Approval
SNK-396 is under clinical development by Synerk and currently in Phase I for Lipid Disorders. According to GlobalData, Phase I …
-
Resiquimod by SURGE Therapeutics for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer): Likelihood of Approval
Resiquimod is under clinical development by SURGE Therapeutics and currently in Phase II for Non Muscle Invasive Bladder Cancer (NMIBC) …
-
COYA-301 by Coya Therapeutics for Alzheimer’s Disease: Likelihood of Approval
COYA-301 is under clinical development by Coya Therapeutics and currently in Phase II for Alzheimer's Disease. According to GlobalData, Phase …